Tag: Eli lilly

With over 40% of American adults classified as obese, medications like Ozempic have seen a surge in demand [1.2.7]. A common question is, **Does Eli Lilly make Ozempic?** The answer is no; Ozempic is manufactured by the Danish pharmaceutical company Novo Nordisk [1.4.2].

In the first half of 2025, the combined sales of tirzepatide, marketed as Mounjaro and Zepbound, reached over $14.7 billion, solidifying its position as the clear answer to the question, **what is the flagship drug of Eli Lilly?**. The dual GIP/GLP-1 receptor agonist has transformed the treatment landscape for both Type 2 diabetes and obesity.

With the list price for a month's supply of Zepbound pens at $1,086.37, many patients are asking a critical question: will Zepbound have a coupon in 2025 to manage this cost? [1.4.8] Official documents confirm savings programs will be active.

With the retail price of Zepbound potentially exceeding $1,000 per month without insurance, managing the cost of this medication is a significant concern for many. Thankfully, there are multiple avenues, including manufacturer programs and strategic pharmacy choices, that can help patients figure out how to reduce the cost of Zepbound.

While the U.S. Food and Drug Administration (FDA) declared the national shortage of the active ingredient in Zepbound resolved in late 2024, real-time availability can still fluctuate at the local pharmacy level. Patients must be persistent to ensure is Zepbound readily available at pharmacies, especially with recent changes impacting insurance coverage and compounded alternatives.

The U.S. Food and Drug Administration (FDA) officially declared the shortage of Zepbound and its active ingredient, tirzepatide, resolved in December 2024 after manufacturer Eli Lilly ramped up production. However, throughout the year, many patients have continued to experience intermittent access issues, leading to persistent questions: **Is there a Zepbound shortage in 2025?**.

In December 2024, the FDA declared the national tirzepatide shortage officially resolved, a significant relief for patients struggling to fill prescriptions. However, many patients continue to ask, “**Is Zepbound on backorder again**?” as they encounter lingering local supply issues.

As of March 19, 2025, the landscape for tirzepatide users has fundamentally changed [1.2.1, 1.2.3]. The question on many minds is: **is compounded tirzepatide really going away?** The short answer is yes, due to decisive action from the U.S. Food and Drug Administration (FDA).

With the market for obesity medications growing rapidly, the high cost of brand-name drugs like Zepbound has many patients asking: how long before Zepbound goes generic? The timeline is governed by a complex web of patent protections and FDA exclusivities that protect the original manufacturer's investment for years.

As of late 2024, the U.S. Food and Drug Administration (FDA) declared the national shortage of tirzepatide, the active ingredient in Zepbound, resolved after months of intermittent supply issues. This positive development addresses the pressing patient question: **Is Zepbound 5mg available?** While the national supply has stabilized, local pharmacy stock and access methods can still vary, making it crucial to understand current purchasing options.